GS 9876

Drug Profile

GS 9876

Alternative Names: GS-9876

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Developer Galapagos NV; Gilead Sciences
  • Class Antirheumatics
  • Mechanism of Action Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 22 Sep 2017 Gilead Sciences plans a phase II trial for Lupus nephritis (Combination therapy) (NCT03285711)
  • 01 May 2017 Phase-II clinical trials in Sjogren's syndrome (In adults, In the elderly) in USA, United Kingdom (PO) (NCT03100942)
  • 25 Apr 2017 Phase-II clinical trials in Cutaneous lupus erythematosus (Combination therapy, In adults, In the elderly, Treatment-experienced) in Canada, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top